Hydrocodone-Chlorpheniramne Er (hydrocodone polistirex/chlorpheniramine polistirex)

Dosage of chlorpheniramine and dexchlorpheniramine should be individualized according to the patient's response and tolerance. Dosage of dexchlorpheniramine maleate is approximately 50% that of chlorpheniramine maleate.

Hydrocodone bitartrate and hydrocodone polistirex are administered orally.

When the extended-release oral suspension containing hydrocodone polistirex and chlorpheniramine polistirex (e.g., Tussionex(R) Pennkinetic(R)) is used, patients and caregivers should be strongly advised to use an accurate, calibrated dosing device to measure doses of the suspension. Use of a household teaspoon as a measuring device could result in overdosage. The extended-release oral suspension should not be diluted with other liquids or mixed with other drugs, since this may alter resin binding, thereby altering the rate of hydrocodone absorption and possibly resulting in toxicity. The extended-release oral suspension should not be given more frequently than every 12 hours; if cough is not controlled, the clinician should be contacted. The extended-release oral suspension should be shaken well before each use.

Chlorpheniramine maleate and dexchlorpheniramine maleate are administered orally.

No dosing information is available for this tab.

No dosing information is available for this tab.

Concomitant use of opiate agonists and benzodiazepines or other CNS depressants (e.g., anxiolytics, sedatives, hypnotics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opiate agonists, alcohol) may result in profound sedation, respiratory depression, coma, and death. Opiate agonist antitussives should be avoided in patients taking benzodiazepines, other CNS depressants, or alcohol. Concurrent use of anticholinergic agents with hydrocodone may produce paralytic ileus. Concomitant use of opiate agonists with serotonergic drugs can cause serotonin syndrome. (See Drug Interactions in the Opiate Agonists General Statement 28:08.08.)

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Safe use of hydrocodone during pregnancy has not been established; therefore, the drug should not be administered to pregnant women unless the possible benefits outweigh the potential risks.

Reproduction studies in animals using dexchlorpheniramine have not been performed to date, but reproduction studies in rabbits and rats using chlorpheniramine maleate dosages up to 50 and 85 times the usual human dosage, respectively, have not revealed evidence of harm to the fetus. Decreased postnatal survival in offspring of rats receiving 33 and 67 times the usual human dosage of chlorpheniramine maleate has been reported. There are no adequate and controlled studies to date using chlorpheniramine or dexchlorpheniramine in pregnant women, and the drugs should be used during the first 2 trimesters only when clearly needed. In one epidemiologic study, use of chlorpheniramine was not associated with an increased risk of teratogenic effects; however, only a limited number of pregnant women received the drug in this study. Because of the risk of severe reactions (e.g., seizures) to antihistamines in neonates, chlorpheniramine or dexchlorpheniramine should not be used during the third trimester.

It is not known whether hydrocodone is distributed into human milk. A decision should be made to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

It is not known whether chlorpheniramine or dexchlorpheniramine is distributed into milk, but other antihistamines (e.g., diphenhydramine) have been detected in milk. Because of the potential for serious adverse reactions to antihistamines in nursing infants, a decision should be made whether to discontinue nursing or chlorpheniramine or dexchlorpheniramine, taking into account the importance of the drug to the woman.

No enhanced messaging available.